We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors.
- Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? (1:46)
- What clinical evidence supports the use of selective IL-23 inhibitors in the treatment of psoriasis? (2:50)
- What are the main safety risks associated with IL‐23 inhibitors in patients with psoriasis? (3:56)
- How is the role of IL-23 inhibitors likely to evolve in the future? (4:28)
Disclosures: Tiago Torres has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the 29th EADV Virtual Congress 2020.
Share this Video
Related Videos In Psoriasis
Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!